Â¥
6.29
Apr 30
Business Description
Baolingbao Biology Co Ltd
NAICS : 325411
SIC : 2833
ISIN : CNE100000FL1
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.83 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 3.34 | |||||
Interest Coverage | 4.06 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.56 | |||||
Beneish M-Score | -2.48 | |||||
WACC vs ROIC |
Growth Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.7 | |||||
3-Year EBITDA Growth Rate | 7.2 | |||||
3-Year EPS without NRI Growth Rate | -3.5 | |||||
3-Year FCF Growth Rate | -21.6 | |||||
3-Year Book Growth Rate | 7.3 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 80.53 | |||||
9-Day RSI | 66.14 | |||||
14-Day RSI | 58.99 | |||||
6-1 Month Momentum % | -23.51 | |||||
12-1 Month Momentum % | -28.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.36 | |||||
Quick Ratio | 0.88 | |||||
Cash Ratio | 0.42 | |||||
Days Inventory | 51.07 | |||||
Days Sales Outstanding | 35.42 | |||||
Days Payable | 42.93 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.27 | |||||
Dividend Payout Ratio | 0.44 | |||||
3-Year Dividend Growth Rate | 38.7 | |||||
Forward Dividend Yield % | 1.27 | |||||
5-Year Yield-on-Cost % | 1.73 | |||||
3-Year Average Share Buyback Ratio | -0.1 | |||||
Shareholder Yield % | 8.88 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 8.1 | |||||
Operating Margin % | 3.65 | |||||
Net Margin % | 2.14 | |||||
FCF Margin % | 4.93 | |||||
ROE % | 2.69 | |||||
ROA % | 1.88 | |||||
ROIC % | 3.28 | |||||
ROC (Joel Greenblatt) % | 5.15 | |||||
ROCE % | 4.05 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 41.93 | |||||
PE Ratio without NRI | 34.37 | |||||
Shiller PE Ratio | 30.95 | |||||
PEG Ratio | 3.51 | |||||
PS Ratio | 0.89 | |||||
PB Ratio | 1.18 | |||||
Price-to-Tangible-Book | 1.25 | |||||
Price-to-Free-Cash-Flow | 18.5 | |||||
Price-to-Operating-Cash-Flow | 8.23 | |||||
EV-to-EBIT | 27.07 | |||||
EV-to-EBITDA | 27.07 | |||||
EV-to-Revenue | 0.94 | |||||
EV-to-FCF | 18.27 | |||||
Price-to-Projected-FCF | 0.89 | |||||
Price-to-DCF (Earnings Based) | 1.62 | |||||
Price-to-DCF (FCF Based) | 1.6 | |||||
Price-to-Median-PS-Value | 0.43 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.02 | |||||
Price-to-Graham-Number | 1.38 | |||||
Price-to-Net-Current-Asset-Value | 20.97 | |||||
Earnings Yield (Greenblatt) % | 3.69 | |||||
FCF Yield % | 5.59 | |||||
Forward Rate of Return (Yacktman) % | 18.97 |